Robert Nelsen – Juno Therapeutics

Robert Nelsen

Director & Co-Founder

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing, and development of more than thirty companies. His seed and early-stage investments include Illumina, Alnylam Pharmaceuticals), Juno Therapeutics, Agios Pharmaceuticals, Sage Therapeutics, Ikaria (acquired by Madison Dearborn), Kythera Biopharmaceuticals, Aviron (acquired by Medimmune), Sapphire Energy, NetBot (acquired by Excite), R2 Technology (acquired by Hologic), XenoPort, Caliper Life Sciences (acquired by PerkinElmer), Bluebird Bio, Trubion Pharmaceuticals (acquired by Emergent BioSolutions), Adolor (acquired by Cubist), deCODE Genetics (acquired by Amgen), Array BioPharma, Nanosys, GenVec, IDUN Pharmaceuticals (acquired by Pfizer), Genomica (acquired by Exelixis), (acquired by United Online), Nura (acquired by Omeros), Receptos, Kilimanjaro Energy, Hua Medicine, VLST, Ensemble Therapeutics, Accelerator, Theraclone Sciences, Fate Therapeutics, NextCODE Health, Bellerophon Therapeutics, Syros Pharmaceuticals, and Everyday Learning Corporation (acquired by Tribune Corp.). Mr. Nelsen is a director of Agios Pharmaceuticals, Juno Therapeutics, Sapphire Energy, Ensemble Therapeutics, Syros Pharmaceuticals, NextCODE Health, and serves as Chairman of Hua Medicine. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.